AGTC to Participate in Upcoming Investor Conferences
August 01 2022 - 4:05PM
Applied Genetic Technologies Corporation (“AGTC” or the “Company”)
(Nasdaq: AGTC), a clinical-stage biotechnology company focused on
the development and potential commercialization of adeno-associated
virus (AAV)-based gene therapies for the treatment of rare and
debilitating diseases with an initial focus on inherited retinal
diseases, today announced that management will be participating in
the following investor conferences:
- BTIG Biotechnology
Conference – New York (August 8, 2022)Jon Lieber, Chief
Financial Officer, will participate in one-on-one investor
meetings.
- Wedbush PacGrow Healthcare
Conference – Virtual (August 9, 2022)Sue Washer, President
and Chief Executive Officer, and Mr. Lieber will participate in
one-on-one investor meetings.
- H.C. Wainwright 2nd Annual
Ophthalmology Conference – Virtual (August 17, 2022)A
presentation with Ms. Washer will be available to view on-demand
beginning on Wednesday, August 17 at 7:00 a.m. ET through the
entirety of the conference.The presentation can be accessed by
visiting http://ir.agtc.com/events-and-presentations. Replays will
be available on the Company's website following the events.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is designing and
constructing critical gene therapy elements and bringing them
together to develop customized therapies with the potential to
address unmet patient needs. AGTC’s most advanced clinical programs
in XLRP and ACHM CNGB3 leverage its technology platform to
potentially improve vision for patients with inherited retinal
diseases. Its preclinical programs build on the AGTC’s AAV
manufacturing technology and scientific expertise. AGTC is
advancing multiple pipeline candidates to address substantial unmet
clinical needs in optogenetics, otology and CNS disorders, and has
entered into strategic collaborations with companies including
Bionic Sight, Inc., an innovator in the emerging field of
optogenetics and retinal coding, and Otonomy, Inc., a
biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology.
IR Contact: David Carey
Lazar FINN PartnersT: (212) 867-1768
david.carey@finnpartners.com
Corporate Contact:Jonathan
LieberChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5778jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024